What is the most likely diagnosis for a patient with lung cancer, severe neutropenia (low white blood cell count), and symptoms of diffuse abdominal pain and diarrhea after chemotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neutropenic Enterocolitis (Typhlitis)

The most likely diagnosis is neutropenic enterocolitis (typhlitis), a life-threatening complication of chemotherapy-induced severe neutropenia that presents with the classic triad of profound neutropenia, fever, and diffuse abdominal pain localizing to the right lower quadrant with diarrhea. 1, 2

Clinical Reasoning

This patient's presentation is pathognomonic for neutropenic enterocolitis:

  • Severe neutropenia (WBC 300/mm³) occurring 1-2 weeks after chemotherapy completion 2, 3
  • Diffuse abdominal pain with right lower quadrant localization and mild guarding 1, 2
  • Diarrhea as part of the gastrointestinal symptom complex 1, 2
  • No antibiotic prophylaxis, increasing infection risk 3

The American Society of Clinical Oncology recognizes typhlitis as the most common cause of acute abdominal pain in neutropenic cancer patients, typically occurring 1-2 weeks after chemotherapy initiation 2, 3. The cecum and terminal ileum are preferentially affected due to chemotherapeutic damage to the intestinal mucosa in the context of absolute neutropenia 1, 4.

Immediate Diagnostic Workup

Obtain contrast-enhanced CT abdomen/pelvis immediately - this is the gold standard showing bowel wall thickening >4 mm (transversal) or >30 mm (longitudinal) in the cecum and terminal ileum 2. CT can also identify pneumatosis intestinalis, pericolic fluid collections, abscesses, or free air suggesting perforation 1.

Additional essential tests include:

  • Blood cultures (at least two sets) before antibiotics 3
  • Stool for C. difficile toxin using two-step approach to exclude concurrent infection 2, 5
  • Abdominal ultrasound if CT unavailable - bowel wall thickening >5 mm is diagnostic, with mortality risk dramatically increasing when thickness exceeds 10 mm (60% vs 4.2%) 1, 2

Management Algorithm

Conservative Medical Management (First-Line)

Start immediately with broad-spectrum antibiotics with anti-pseudomonal coverage 2:

  • Piperacillin-tazobactam 4.5g IV every 6 hours OR 2, 6
  • Meropenem 1g IV every 8 hours 2, 7

Supportive measures 1, 2:

  • Complete bowel rest with nasogastric suction 1, 8
  • Total parenteral nutrition 1, 2, 8
  • IV hydration and electrolyte correction 2, 5
  • Consider G-CSF to accelerate neutrophil recovery 2, 9

Critical: Avoid laxatives or antidiarrheal agents - these can precipitate perforation 8.

Surgical Intervention Indications

Obtain early surgical consultation but reserve intervention for 2, 5:

  • Bowel perforation or free air on imaging 1, 2
  • Intestinal obstruction 2, 8
  • Massive hemorrhage 8, 9
  • Abscess formation 1, 8
  • Progressive clinical deterioration despite 24-48 hours of maximal medical therapy 2, 5

Surgical approach when indicated: Right hemicolectomy with ileostomy and mucous fistula - failure to remove necrotic focus is fatal in these immunocompromised patients 8.

Prognosis and Monitoring

Mortality rates reach 29.5% in patients with positive radiologic findings, emphasizing the critical importance of early CT scanning and aggressive medical management 2, 3. Serial abdominal examinations every 4-6 hours are essential to detect clinical deterioration 5. Repeat imaging within 48 hours if no clinical improvement 5.

Common Pitfalls to Avoid

  • Do not assume normal vital signs exclude serious pathology - fever and peritoneal signs may be absent or subtle in immunocompromised patients 5
  • Do not delay CT imaging - this can lead to missed life-threatening complications 5
  • Do not withhold antibiotics pending culture results if the patient appears systemically ill 5
  • Do not use antimotility agents until infectious causes are excluded 5

The incidence of neutropenic enterocolitis is increasing, particularly with high-dose chemotherapy regimens including taxanes and cytarabine 1, 10. Gram-negative bacteria, especially Pseudomonas aeruginosa, remain the main causative pathogens with high associated mortality 3, 10.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Typhlitis Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Neutropenic Fever Causes and Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Neutropenic enterocolitis.

Hematology/oncology clinics of North America, 2010

Guideline

Management of Abdominal Pain with Diarrhea and Leukocytosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Typhlitis: selective surgical management.

American journal of surgery, 1986

Research

Neutropenic Enterocolitis: Case report and literature review.

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 2022

Research

Neutropenic enterocolitis after high-dose chemotherapy and autologous stem cell transplantation: incidence, risk factors, and outcome.

Transplant infectious disease : an official journal of the Transplantation Society, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.